Form D · Biotechnology
First Wave Bio, Inc.
New York, NY · CIK 0001783499
Offering snapshot reported Aug 19, 2019 · SEC filing
- Reported sold
- $2.62M Offering amount: $5M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 6, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 19, 2019 | Initial | $2,617,503 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-346884
Source: Form D, filed Aug 19, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Glick | Director |
| David Hoffman | Director, Executive |
| Leonard Oremland | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Covington & Burling Llp 620 Eighth Avenue
New York, NY, 10018-1405
New York, NY, 10018-1405